Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Estrone | Estrone may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Estradiol | Estradiol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Mestranol | Mestranol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Estriol | Estriol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Tibolone | Tibolone may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Zeranol | Zeranol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Equol | Equol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Promestriene | Promestriene may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Formononetin | Formononetin may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Estetrol | Estetrol may increase the thrombogenic activities of Rovalpituzumab tesirine. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Rovalpituzumab tesirine. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rovalpituzumab tesirine. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Rovalpituzumab tesirine. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Rovalpituzumab tesirine. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Rovalpituzumab tesirine. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rovalpituzumab tesirine. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rovalpituzumab tesirine. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Rovalpituzumab tesirine. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rovalpituzumab tesirine. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Rovalpituzumab tesirine. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Rovalpituzumab tesirine. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Rovalpituzumab tesirine. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rovalpituzumab tesirine. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rovalpituzumab tesirine. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Rovalpituzumab tesirine. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rovalpituzumab tesirine. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rovalpituzumab tesirine. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Rovalpituzumab tesirine. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rovalpituzumab tesirine. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Rovalpituzumab tesirine. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Rovalpituzumab tesirine. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Rovalpituzumab tesirine. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rovalpituzumab tesirine. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rovalpituzumab tesirine. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Rovalpituzumab tesirine. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Rovalpituzumab tesirine. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Rovalpituzumab tesirine. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Rovalpituzumab tesirine. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Rovalpituzumab tesirine. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Rovalpituzumab tesirine. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Rovalpituzumab tesirine. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Rovalpituzumab tesirine. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Rovalpituzumab tesirine. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Rovalpituzumab tesirine. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Rovalpituzumab tesirine. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Rovalpituzumab tesirine. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Rovalpituzumab tesirine. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Rovalpituzumab tesirine. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Rovalpituzumab tesirine. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Rovalpituzumab tesirine. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Rovalpituzumab tesirine. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Rovalpituzumab tesirine. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Rovalpituzumab tesirine. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Rovalpituzumab tesirine. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Rovalpituzumab tesirine. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Rovalpituzumab tesirine. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Rovalpituzumab tesirine. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Rovalpituzumab tesirine. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Rovalpituzumab tesirine. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Rovalpituzumab tesirine. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Rovalpituzumab tesirine. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Rovalpituzumab tesirine. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Rovalpituzumab tesirine. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Rovalpituzumab tesirine. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Rovalpituzumab tesirine. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Rovalpituzumab tesirine. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Rovalpituzumab tesirine. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Rovalpituzumab tesirine. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Rovalpituzumab tesirine. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Rovalpituzumab tesirine. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Rovalpituzumab tesirine. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Rovalpituzumab tesirine. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Rovalpituzumab tesirine. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Rovalpituzumab tesirine. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Rovalpituzumab tesirine. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Rovalpituzumab tesirine. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Rovalpituzumab tesirine. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Rovalpituzumab tesirine. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Rovalpituzumab tesirine. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Rovalpituzumab tesirine. |